ClinicalTrials.gg
Not yet recruitingNCT07450404NeuroPKVAPUpdated Mar 4, 2026

PK/PD Target Attainment of Ceftriaxone for the Prevention of Early Ventilator-associated Pneumonia in Neurologically Injured Patients

An observational study in Early Ventilator Associated Pneumonia and Acute Brain Injuries, sponsored by Central Hospital, Nancy, France. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Central Hospital, Nancy, France · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Planned enrollment
27th of 33
60 · median 268
Started
2026
with 4 others
Observational
33 of 80
9 open now
Primary completion
2027-09
later than 15 of 21 live
Registered
78th of 80
by date
Lead sponsor
2 of 80
Central Hospital, Nancy, France

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 27th largest by planned enrollment of the 33 observational ones that give a count, is one of 5 that started in 2026, is one of 33 observational ones, reaches primary completion later than 15 of the 21 other live ones, and was the 78th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

Critically ill patients admitted for acute brain injury are exposed to many heath-care associated infections such as ventilator associated pneumoniae (VAP). The PROHYVAP study, published in 2024 reported that a single dose of CEFTRIAXONE as an antibiotic prophylaxis could reduce the incidence of early VAP (VAP that occured between day 2 and day 7 of mechanical ventilation).

However, patients with acute brain injury also presented frequently augmented renal clearance (ARC), which could affect the pharmacokinetic and pharmacodynamic target attainment (PK/PD) of antibiotic prophylaxis.

This study aims to analyse the PK/PD target attainment after one dose of CEFTRIAXONE in critically ill patients with acute brain injury and to describe the effect of ARC on PK/PD target attainment during early VAP.

03

Conditions studied

  • Early Ventilator Associated Pneumonia
  • Acute Brain Injuries

Keywords

  • Antibiotic prophylaxis
  • ventilator associated pneumonia
  • augmented renal clearance
  • PK/PD target attainment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients admitted in intensive care unit for an acute brain injury caused by a traumatic brain injury or a vascular cerebral disease (ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage) with a Glasgow coma scale \< 12 and needed a mechanical ventilation for 48 hours or more, started in the first 12 hours.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Admitted in intensive care unit for acute brain injury, including traumatic brain injury and cerebral vascular disease
  • Glasgow coma scale inferior to 12
  • Orotracheal intubation in first 12 hours of admission
  • Needed of invasive mechanical ventilation for at least 48 hours

Exclusion criteria

Exclusion Criteria:

  • Acute brain injury related to tumoral or infectious process
  • Antibiotic therapy administered before acute brain injury for an other pathology
  • Patients with a risk of multiresistance bacteria contamination (stay in a risk area in the past 3 months, antibiotic therapy with fluoroquinolone or betalctamine in the past 3 months, hospitalization in last month before admission, documented contaminationwith multiresistance bacteria, immunodepression)
  • Patients with hish risk of death in the first 48 hours
  • Patients with a beta-lactams reported allergy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
28 Days
Patient registry
Yes

Groups and cohorts

  • Critically ill patients with acute brain injury

    Patients with severe acute brain injury defined by a Glasgow coma scale \< or = 8, admitted to the intensive care unit and needed invasive mechanical ventilation for at least 48 hours.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with PK/PD target attainment

    Proportion of patients with serum concentrations of CEFTRIAXONE above the minimal inhibitory concentration (MIC) of 4 mg/mL (in case of undocumented VAP), or \> 4 times the MIC of documented bacteria.

    Time frame: 24 hours

Secondary outcomes

  1. Impact of the PK/PD target attainment on the incidence of early ventilator associated pneumoniae

    Time frame: Day 7

  2. Association between augmented renal clearance and PK/PD target attainment

    Time frame: 24 hours

  3. Association between hyperbilirubinemia and PK/PD target attainment

    Time frame: 24 hours

  4. Association between PK/PD target attainment and day 28 mortality

    Time frame: Day 28

  5. Association between PK/PD target attainment and ICU length of stay

    Time frame: 3 months

  6. Incidence of multi drug resistance bacteria

    Time frame: Day 28

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2027, 18 months later.

Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 18 months is close to that.

Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Mar 4, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07450404
Responsible party
STEIB Maureen (Assistante Spécialiste, Central Hospital, Nancy, France) — Principal investigator
First posted
Mar 4, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
Sep 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Maureen Steib, MD
Contact
m.steib@chru-nancy.fr
+33 3 83 85 10 45
Emmanuel NOVY, MD,PhD
study director · Central Hospital, Nancy, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion